Pathos CEO Iker Huerga Shares How AI Can Move Promising Science Closer to Patients
How can AI help move promising science closer to patients?
Pathos CEO Iker Huerga takes up that question in a recent Forbes article on how biotech and pharma are adopting AI. He describes how Pathos uses AI agents to steer clinical trials in real time and to make early decisions on whether programs should continue, and he notes that about 90% of clinical trial failures happen in Phase 2 or 3, not in discovery.
For leadership teams, the practical challenge is connecting data, clinical judgment, and execution so that new capabilities lead to better decisions.
Congratulations to the Pathos team on the coverage.
